The role of cytoreduction surgery in advanced ovarian cancer (review)

Cover Page

Cite item

Full Text

Abstract

The published results of primary and interval debulking surgery in advanced epithelial ovarian cancer are discussed. According to meta-analyses and retrospective studies primary cytoreduction without macroscopic residual tumor has the best results. If the size of the largest residual tumor is more than 1 cm, primary debulking provides no benefit. Published randomized trials didn’t prove benefits of primary debulking surgery.

About the authors

R K Tandelov

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: romanyh@yandex.ru
аспирант каф. онкологии фак-та дополнительного профессионального образования, клиническая база - гинекологическое отд-ние НИИ КО 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

V Yu Sel'chuk

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: onkofpdo@gmail.com
д-р мед. наук, проф., зав. каф. онкологии фак-та дополнительного профессионального образования, глав. врач клинических институтов 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

K Yu Morkhov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: oncogyn@ronc.ru
канд. мед. наук, ст. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V M Nechushkina

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: oncogyn@ronc.ru
д-р мед. наук, проф. каф. онкологии, ст. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V V Kuznetsov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., вед. науч. сотр. гинекологического отд-ния НИИ КО 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. М.: Издательская группа РОНЦ, 2015
  2. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 163-8. doi: 10.1111/j.1525-1438.2003.13354.x
  3. Meigs J.V. Tumors of the Female Pelvic Organs. New York, NY, Macmillan, 1934.
  4. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-4.
  5. Pölcher M, Zivanovic O, Chi D.S. Cytoreductive surgery for advanced ovarian cancer. Womens Health (Lond) 2014; 10 (2): 179-90. doi: 10.2217/whe.14.4
  6. Omura G, Blessing J.A, Ehrlich C.E et al. A randomized trial of cyclophosphamide and doxorubicinum with or without cisplatin in advanced ovarian carcinoma. Cancer 1986; 57 (9): 1725-30. doi: 10.1002/1097-0142(19860501)57:9
  7. Omura G.A, Brady M.F, Homesley H.D et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9 (7): 1138-50. doi: 10.1200/JCO.1991.9.7.1138
  8. Chi D.S, Eisenhauer E.L, Lang J et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006; 103 (2): 559-64. doi: 10.1016/j.ygyno.2006.03.051
  9. Hoskins W.J, Bundy B.N, Thigpen J.T, Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 1992; 47 (2): 159-66. doi: 10.1016/0090-8258(92)90100-W
  10. Eisenkop S.M, Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001; 82 (3): 435-41. doi: 10.1006/gyno.2001.6313
  11. Bristow R.E, Tomacruz R.S, Armstrong D.K et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20 (5): 1248-59. doi: 10.1200/jco.2002.20.5.1248
  12. Bristow R.E, Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103 (3): 1070-6. doi: 10.1016/j.ygyno.2006.06.025
  13. Чубенко В.А. Перспективные методы лечения злокачественных новообразований. Практическая онкология. 2007; 32 (4): 228-35.
  14. Skipper H.E. Adjuvant chemotherapy. Cancer 1978; 41 (3): 936-40. doi: 10.1002/1097-0142(197803)41:3
  15. Goldie J.H, Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63 (11-12): 1727-33.
  16. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10 (6): 370-81. doi: 10.1634/theoncologist.10-6-370
  17. Schorge J.O, McCann C, Del Carmen M.G. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol 2010; 3 (3): 111-7. doi: 10.3909/riog0111
  18. Chi D.S, Eisenhauer E.L, Zivanovic O et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009; 114 (1): 26-31. doi: 10.1016/j.ygyno.2009.03.018
  19. Vergote I, Tropé C.G, Amant F et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363 (10): 943-53. doi: 10.1056/NEJMoa0908806
  20. Chi D.S, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124 (1): 10-4. doi: 10.1016/j.ygyno.2011.08.014
  21. Морхов К.Ю., Нечушкина В.М., Кузнецов В.В. Хирургическое лечение рака яичников. Практическая онкология. 2014; 60 (4): 153-7.
  22. Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386 (9990): 249-57. doi: 10.1016/S0140-6736(14)62223-6

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies